Enrollment Velocity vs Forecast
Current pace is 93% of plan.
Unified execution surface for sponsor-controlled clinical development from concept through submission and inspection readiness. This workspace exists to enforce consistent clinical execution with accountable ownership, governed evidence, and inspection-ready traceability across the study lifecycle. It supports business and regulatory requirements by connecting operations, quality, submissions, and financial controls in a single system where handoffs are explicit and auditable. Users can proceed by filtering scope, reviewing linked artifacts and actions, and routing escalations with defined approval gates and signature meaning.
Current pace is 93% of plan.
Sites not activated due to contracts, docs, or SIV scheduling.
Open follow-ups linked to visits require owner confirmation.
Artifacts flagged for metadata or filing-quality checks.
KRI signals trending up with CAPA linkage required.
Cross-system mismatches open across EDC/IRT/Lab/eCOA.
Non-green vendor SLA indicators across critical services.
Portfolio spend to date with accrual reconciliation controls.
Navigate portfolio → study → country → site → subject/vendor/doc/task for evidence-backed decision making.
Enrollment velocity vs forecast, site activation bottlenecks, and visit backlog are computed from deterministic operational records.
TMF completeness/timeliness/quality trends, KRI alert pressure, data reconciliation aging, and vendor SLA heatmap are available in one command surface.
Budget burn and accrual variance are rolled up by portfolio, then drill-down links move through study, country, site, and subject/vendor/document levels.